促排卵与宫腔内人工授精后的孕酮黄体支持:更新的系统综述与Meta分析
本更新的系统综述与Meta分析纳入11项试验、2842例患者共4065个周期,评估促排卵与宫腔内人工授精后外源性孕酮黄体支持对活产的影响。在促性腺激素促排卵患者中,孕酮补充组的临床妊娠(RR 1.56,95%CI 1.21-2.02)和活产(RR 1.77,95%CI 1.30-2.42)更可能发生,每周期活产分析结果持续(RR 1.59,95%CI 1.24-2.04)。克罗米芬或克罗米芬联合促性腺激素周期中,孕酮支持对临床妊娠无获益(RR 0.85,95%CI 0.52-1.41;RR 1.26,95%CI 0.90-1.76)。
要点
- 促性腺激素促排卵+IUI后孕酮黄体支持可提高活产(RR 1.77,95%CI 1.30-2.42)。
- 每11例患者治疗可额外获得1例活产。
- 克罗米芬或克罗米芬联合促性腺激素周期中孕酮支持无临床妊娠获益。
核心结论
- 孕酮黄体支持对促性腺激素促排卵的IUI周期患者有益,每治疗11例患者可额外获得1例活产。
- 孕酮支持对克罗米芬或克罗米芬联合促性腺激素促排卵的患者无获益。
研究设计与样本
- 更新的系统综述与Meta分析,纳入11项符合入选标准的试验,共2842例接受促排卵与宫腔内人工授精的不孕患者、4065个周期。
- 样本量较前次Meta分析增加一倍以上。
主要发现
- 促性腺激素促排卵患者中,孕酮补充组的临床妊娠更可能发生(RR 1.56,95%CI 1.21-2.02)。
- 促性腺激素促排卵患者中,孕酮补充组的活产更可能发生(RR 1.77,95%CI 1.30-2.42)。
- 按每IUI周期分析活产,结果持续(RR 1.59,95%CI 1.24-2.04)。
- 克罗米芬促排卵患者中,孕酮支持对临床妊娠无获益(RR 0.85,95%CI 0.52-1.41)。
- 克罗米芬联合促性腺激素促排卵患者中,孕酮支持对临床妊娠无获益(RR 1.26,95%CI 0.90-1.76)。
关键数值与推荐
- 促性腺激素促排卵:临床妊娠RR 1.56(95%CI 1.21-2.02),活产RR 1.77(95%CI 1.30-2.42)。
- 每IUI周期活产:RR 1.59(95%CI 1.24-2.04)。
- 克罗米芬促排卵:临床妊娠RR 0.85(95%CI 0.52-1.41)。
- 克罗米芬联合促性腺激素促排卵:临床妊娠RR 1.26(95%CI 0.90-1.76)。
- 需治疗人数为11例患者可额外获得1例活产。
临床怎么用
- 对促性腺激素促排卵行IUI的患者,孕酮黄体支持可获得活产获益。
- 对克罗米芬或克罗米芬联合促性腺激素促排卵的患者,孕酮黄体支持未显示临床妊娠获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of progesterone (P) for luteal phase support after ovulation induction (OI) and intrauterine insemination (IUI). DESIGN: An updated systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Patients undergoing OI-IUI for infertility. INTERVENTION(S): Exogenous P luteal support after OI-IUI. MAIN OUTCOME MEASURE(S): Live birth. RESULT(S): Eleven trials were identified that met inclusion criteria and constituted 2,842 patients undergoing 4,065 cycles, more than doubling the sample size from the previous meta-analysis. In patients receiving gonadotropins for OI, clinical pregnancy (relative risk [RR] 1.56, 95% confidence interval [CI] 1.21-2.02) and live birth (RR 1.77, 95% CI 1.30-2.42) were more likely in P supplemented patients. These findings persisted in analysis of live birth per IUI cycle (RR 1.59, 95% CI 1.24-2.04). There were no data on live birth in clomiphene citrate or clomiphene plus gonadotropin cycles. There was no benefit on clinical pregnancy with P support for patients who underwent OI with clomiphene (RR 0.85, 95% CI 0.52-1.41) or clomiphene plus gonadotropins (RR 1.26, 95% CI 0.90-1.76). CONCLUSION(S): Progesterone luteal phase support is beneficial to patients undergoing ovulation induction with gonadotropins in IUI cycles. The number needed to treat is 11 patients to have one additional live birth. Progesterone support did not benefit patients undergoing ovulation induction with clomiphene citrate or clomiphene plus gonadotropins.
引用
- Green KA, Zolton JR, Schermerhorn SM, et al. Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis. Fertil Steril. 2017. PMID: 28238492. doi:10.1016/j.fertnstert.2017.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。